Wet-Granulation Binder Function in Immediate-Release Tablet Manufacturing

High-shear wet granulation of immediate-release tablet formulations uses Copovidone VA64 as a solution binder at 2.5–5.0% w/w of dry granule mass, with the binder solution prepared at 8–12% w/w solids in purified water. The 10% w/w aqueous solution has viscosity in the range of 5–10 mPa·s at 25°C, which permits atomization through 0.8–1.2 mm spray nozzles without intermittent blockage. The excipient is not the active API; it is a pharmacopoeial copolymer controlled under the USP-NF Copovidone monograph and Ph. Eur. Copovidone monograph. Granulation is conducted in a high-shear mixer such as a Diosna P1/6 or GEA Aeromatic-Fielder PMA series at impeller speed 300–500 rpm and chopper speed 1500–3000 rpm, with wet massing time limited to 60–180 s because over-wetting above 180 s produces dense granule nuclei that retard disintegration. The wet mass is discharged through a 1.6–2.0 mm sieve and dried in a fluid-bed dryer at inlet air temperature 60–70°C until loss on drying reaches 1.0–2.0% w/w. Dried granules are screened through 1.0–1.5 mm mesh, blended with crospovidone at 2–4% w/w and magnesium stearate at 0.5–1.0% w/w, then compressed on a rotary tablet press to hardness 80–120 N. Tablet disintegration is verified using USP 701, dissolution using USP 711, and content uniformity using USP 905. The terminal dosage form is immediate-release tablet for oral administration. In-process control of granulation torque or power consumption is maintained under 21 CFR 211.110 to detect batch-to-batch variation in wet mass progression; product temperature during drying is held within ±2°C of the 38–42°C target to prevent case hardening and binder migration.

When Roller Compaction Requires a Dry Binder with Low Glass Transition Sensitivity

In roller compaction of moisture-labile APIs that cannot tolerate aqueous granulation, Copovidone VA64 is dry-blended at 5–15% w/w of the total formulation mass to increase ribbon strength without the dissolution lag commonly associated with povidone K30. Compaction is performed on a Gerteis Mini-Pactor or Alexanderwerk WP120 roll press at roll pressure 8–14 kN/cm, roll speed 2–5 rpm, and roll gap 2–4 mm. The resulting ribbon density is controlled at 0.95–1.15 g/cm³; ribbons above 1.20 g/cm³ exhibit reduced re-compactibility due to work hardening of the copolymer. The compacted ribbons are milled through 0.8–1.25 mm oscillating sieves, and the granulate is blended with disintegrant and lubricant before compression. Tablet friability is assessed using Ph. Eur. 2.9.7, and content uniformity using USP 905. Process design space is documented per ICH Q8(R2) to justify roll pressure and gap limits. The terminal product is high-dose immediate-release tablet for moisture-labile APIs, where dry granulation prevents hydrolytic degradation during processing. Experience on production-scale roll presses indicates that ribbon splitting becomes significant below 6 kN/cm when the binder level is below 5% w/w, a failure mode requiring real-time ribbon density monitoring. The fine fraction below 150 μm is held below 30% w/w to prevent feed shoe segregation and tablet weight variation.

During hot-melt extrusion of BCS II APIs with crystallization tendency, Copovidone VA64 functions as a matrix polymer at drug-to-polymer ratios from 1:1 to 1:4 w/w, corresponding to drug load 20–50% w/w. The glass transition temperature of the polymer is 105–110°C, allowing processing at zone temperatures 120–160°C without thermal degradation of heat-labile APIs. Extrusion is performed on a co-rotating twin-screw extruder such as a Leistritz ZSE 18 HP with L/D ratio 40:1 at screw speed 100–300 rpm, melt pressure 20–50 bar, and torque 2–8 N·m. Prior to feeding, Copovidone VA64 and API are pre-dried at 40°C and ≤30% RH for 12 h because residual moisture acts as a plasticizer, lowering the melt glass transition and shifting phase separation onset. The molten strand is extruded through a 2–4 mm die, air-cooled, pelletized, and milled to 125–500 μm granules. X-ray powder diffraction is used to confirm absence of crystalline API peaks, residual moisture is held below 1.0% w/w by Karl Fischer titration, and dissolution rate is measured by USP 711 in biorelevant media. Equipment qualification follows 21 CFR 211.65, and elemental impurity control follows ICH Q3D. The terminal dosage form is amorphous solid dispersion tablet or capsule for oral administration. Process failure modes include torque spikes when feed rate exceeds 500 g/h on an 18 mm extruder, and die-plate blockage when melt viscosity exceeds 10,000 Pa·s. Compatibility boundaries exclude prolonged exposure to aqueous media below pH 2 or above pH 12, where ester hydrolysis of the vinyl acetate comonomer occurs.

Aqueous film coating of compressed tablets with Copovidone VA64 at 5–10% w/w solids in purified water produces clear coatings at weight gain 2–5% w/w of tablet core mass. The coating dispersion is prepared by dissolving the copolymer with a plasticizer such as PEG 400 or triethyl citrate at 10–20% w/w of polymer solids to prevent film cracking. Coating is applied in a side-vented pan coater such as an O'Hara Labcoat 650 or Glatt coater with inlet air temperature 55–65°C, exhaust air temperature 45–50°C, atomization air pressure 1.5–2.0 bar, spray rate 5–15 g/min per gun, and pan speed 5–10 rpm. Exhaust temperatures above 50°C cause film tackiness and tablet picking; exhaust temperatures below 40°C retain moisture and increase film porosity. Tablet disintegration and dissolution after coating are verified using USP 701 and USP 711, with acceptance criteria unchanged from the uncoated core. The terminal product is film-coated tablet for oral administration. The coating process is constrained by the need to maintain exhaust relative humidity below 30%, because Copovidone VA64 absorbs atmospheric moisture and may become adhesive on the tablet bed. Coating uniformity is evaluated by scanning electron microscopy on cross-sectioned tablets, with film thickness variation held within ±15% of the target value.

How Does Copovidone VA64 Control Film Tensile Strength in Oral Soluble Films?

For oral soluble films cast from aqueous-ethanolic solutions, Copovidone VA64 is incorporated at 35–65% w/w of dry film mass, combined with glycerol or propylene glycol at 10–20% w/w of polymer mass as plasticizer. The casting solution is prepared at 15–25% w/w solids in a water/ethanol mixture, deaerated under vacuum at 200 mbar for 30 min, cast by knife-over-roll coater to wet thickness 400–600 μm, and dried at 60–80°C for 10–20 min to residual moisture 3–6% w/w. Dry film thickness is 50–100 μm, and tensile properties are measured by ASTM D882 to ensure tensile strength 20–40 MPa and elongation at break 5–15%. Residual ethanol is controlled under ICH Q3C; the Class 3 limit for ethanol is 5000 ppm. Drug release from the finished film is tested using USP 711 with Apparatus 2 and sinker. The terminal product is unit-dose oral soluble film for oral administration. Operating boundaries include storage of finished films in sealed aluminum pouches below 25°C and ≤30% RH to prevent brittleness from moisture loss; casting solution viscosity above 5000 mPa·s at 25°C produces edge defects and non-uniform thickness.

Applying Copovidone VA64 in Fluidized-Bed Spray Granulation for Capsule Fill Blends

Fluidized-bed top-spray granulation for hard gelatin or HPMC capsule fill blends employs Copovidone VA64 as aqueous binder at 5–10% w/w solids, sprayed at 10–30 g/min in a Glatt GPCG 3.1 or equivalent. Inlet air temperature is 65–75°C, product temperature 35–40°C, and final granule loss on drying is 1.5–2.5% w/w. The dry binder addition level is 2–6% w/w of granule mass. Resulting granules exhibit bulk density 0.40–0.55 g/cm³ and Carr index 10–15%, enabling reproducible capsule filling on dosator and tamping-pin machines at speeds above 60,000 capsules/h. Granule size distribution is controlled by sieve analysis with target D50 150–300 μm; the fraction below 75 μm is held below 12% w/w to prevent fill weight variation. Encapsulated product is checked for disintegration using USP 701, dissolution using USP 711, and content uniformity using USP 905. The terminal product is hard gelatin or HPMC capsule for oral administration. Process boundaries include outlet air humidity above 50% RH causing agglomeration and non-uniform granule growth; spray rate above 30 g/min at 5% w/w solids produces overwetting and bed collapse in the receiver cone. Filter bag shaking is set to 5–10 s per 60 s cycle to prevent fines buildup on process filters.